By Dr. Priyom Bose, Ph.D. By replacing both breathing and circulatory buffering, a novel artificial lung bought critical time after lung removal, revealed irreversible damage, and made transplantation ...

Learn more about whether Arrowhead Pharmaceuticals, Inc. or Regeneron Pharmaceuticals, Inc. is a better investment based on ...

Onvansertib in combination with both chemo/bev regimens was well-tolerated. There were no major or unexpected toxicities observed and no additive adverse events. Grade 3 or higher adverse events were ...

Discover J&J’s pipeline strategy for 2026 as it it projects that its sales for the year will be between $100 billion and $101 ...

European equities began the last week of January in a sour mood, with investors concerned on January 26 about rising geopolitical tensions in anticipation of a Federal Reserve policy meeting and a ...

Two internationally renowned experts are coming to Birmingham as part of a Government drive to attract global research talent to the UK.

Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patie ...

Cancer treatment is entering a new era, driven by advances in precision medicine, AI, and targeted therapies known as theranostics. In this episode of Today in Tech, Keith Shaw speaks with Douglas ...

How do electrical signals become "about" something? Through purely physical processes, neural networks transform activity ...

Biotech stocks are in focus as analysts track upcoming clinical data and regulatory decisions in autoimmune and rare disease ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. 5, 2026 /CNW/ — USANewsGroup.com News Commentary – The FDA isn’t just approving drugs; they are completely reshaping the landscape.